Viyash Scientific Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company focuses on reducing debt and maximizing cash flow generation as key priorities for FY27. - They emphasize disciplined working capital management and efficient capital allocation to drive sustainable growth. - The balance sheet is described as strong, with healthy liquidity and comfortable leverage, giving flexibility to pursue growth opportunities both organic and inorganic. - The financial strategy includes lowering finance burden and optimizing tax structures, without indicating plans for fresh fundraising. - Any significant updates or plans regarding fundraising may be addressed in upcoming investor meetings as hinted by management.

- There is ongoing and planned capex for capacity expansion, especially in Viyash's manufacturing facilities, awaiting approvals to realize further synergies (mentioned on Page 13). - Significant investment is planned in R&D, particularly in finished product formulation for both human health and animal health sectors, focusing on complex molecules (Page 14). - Expansion of R&D team and resources, especially for animal health formulation, accompanied by increased capex (Page 17). - Building and investing in an oncology R&D lab for new product development (Page 8). - Strategic focus includes manufacturing expansion at Spain and debottlenecking capacity at Turkey manufacturing facilities (Page 4). - Overall, capex is aimed at strengthening merger synergies, operational performance, and driving sustainable growth (Page 6). Depreciation related to prior intangibles amortization will reduce, and new capex depreciation is expected to maintain a similar run rate without substantial increase (Page 17).

- API business to achieve double-digit growth next year, driven by approvals in human health APIs and stepped-up animal health API sales. - Animal health business growing after 5 years of stagnation, increasing from ~INR350 crores to INR400 crores, with strong growth expected. - Formulation business growing 18% in FY26, with focus on complex products and internal APIs supporting sustainable margin expansion. - CDMO business expected to grow 30-40% next year, with 8-10 innovators engaged and approvals for new products coming. - Overall company targets 15% annual growth rate over the next 2-3 years and aims to reach EBITDA of INR1,000 crores in that timeframe. - Expansion efforts include manufacturing capacity debottlenecking in Spain and Turkey, R&D team and capex increases especially in animal health, and strategic market expansion in Europe and other regions.

- EBITDA growth target: Aim to reach INR1,000 crores in 2-3 years, with internal target around FY27-FY28. - Annual growth rate: Expected to be around 15%, supported by various business levers across formulation, API, and CDMO. - Operating margins: Confident in maintaining current margin levels (~20% EBITDA margin), balancing margin with growth and increased R&D investments. - Profit after tax: Substantial growth observed, PAT increased over 14x to INR225 crores in FY26, with tax rate forecasted around 26-27% going forward. - Quality of growth: Focus on high-value API and animal health formulations with double-digit growth expected next year. - Synergies: Annual synergy benefits tracking INR50-60 crores, expected to rise to INR125-150 crores in next 12-18 months, improving profitability. - Capex impact: Future depreciation expected to decrease from INR100 crores to ~INR35 crores on amortization, with new capex not significantly increasing depreciation burden.

The transcript does not explicitly mention the current or expected order book or pending orders in specific figures. However, some related insights can be summarized: - CDMO business is growing with 8 to 10 innovator clients and multiple products awaiting approval, expected to launch starting end of FY26. - There is strong growth potential in innovator business with a forecasted 30%-40% growth in FY27. - The company has filed multiple complex and high-potent products over the last few years that are now receiving regulatory approvals. - Expansion in R&D and manufacturing capacities to support companion animal health and formulation businesses signal pipeline growth. - Synergies and integration efforts post-merger are progressing better than anticipated, potentially accelerating order execution. No explicit mention of orderbook size or pending orders is available in the transcript.